Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
Ney Carter Borges/LinkedIn
Apr 14, 2026, 16:58

Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:

“NLRP3 Inhibition in Atherosclerosis: Early Clinical Signal Beyond Lipids

Targeting residual inflammatory risk has become a central challenge in contemporary cardiovascular prevention, particularly in patients who achieve optimal LDL-C control yet remain at elevated risk.

Within this framework, the NLRP3 inflammasome has emerged as a pivotal upstream regulator of vascular inflammation, orchestrating the IL-1B-IL-6-CRP signaling cascade that drives plaque progression, instability, and eventual clinical events.

Early clinical evidence with the oral NLRP3 inhibitor VTX3232 provides a compelling proof-of-concept for this therapeutic strategy.

In a randomized, double-blind phase 2a trial involving individuals with obesity and heightened cardiometabolic risk, treatment with VTX3232 led to profound reductions in inflammatory biomarkers, including up to a ~78% decrease in hsCRP and significant suppression of IL-6 levels.

Notably, these anti-inflammatory effects occurred independently of weight loss, underscoring a mechanism distinct from metabolic modulation.

When combined with semaglutide, VTX3232 demonstrated additive reductions in hsCRP, IL-6, lipoprotein(a), and fibrinogen, suggesting a complementary role alongside established cardiometabolic therapies. These findings reinforce the concept of targeting inflammation as an orthogonal axis of risk reduction.

However, current evidence remains limited to biomarker modulation, with no demonstrated impact on hard cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality.

While mechanistically robust and clinically promising, the ultimate role of NLRP3 inhibition in atherosclerosis will depend on large-scale, event-driven trials.

Reference:

  • Ventyx Biosciences. Phase 2a Study of VTX3232 in Cardiometabolic Risk (ACC 2026 Presentation);
  • Molecular Metabolism (2025);
  • Healio Cardiology News (2026).”

Ney Carter Borges

More posts featuring Ney Carter Borges on Hemostasis Today.

Atherosclerosis Blood Cardiology fibrinogen Health Hematology Hemostasis Hemostasis News Hemostasis Today hsCRP IL-6 LDL-C Lipoprotein(a) Medicine Ney Carter Borges NLRP3 stroke thrombosis
NewsFeed